Rapid Micro Biosystems, Inc.
NASDAQ•RPID
CEO: Mr. Robert G. Spignesi Jr.
セクター: Healthcare
業種: Medical - Devices
上場日: 2021-07-15
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
連絡先情報
1001 Pawtucket Boulevard West, Suite 280, Lowell, MA, 01854, United States
978-349-3200
時価総額
$97.48M
PER (TTM)
-2.0
23.7
配当利回り
--
52週高値
$4.94
52週安値
$2.00
52週レンジ
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025
財務ダッシュボード
Q4 2025 データ
売上高
$11.28M+0.00%
直近4四半期の推移
EPS
-$0.28+0.00%
直近4四半期の推移
フリーCF
-$2.46M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Total Revenue Growth Total revenue reached $33.59M USD, up 19.7% driven by increased system placements and consumable sales.
Recurring Revenue Stability Recurring revenue totaled $17.84M USD, showing 15.5% growth, supporting financial stability and future outlook.
Cash Flow Improvement Cash used in operating activities improved to $(31.06M) USD, a $13.1M decrease versus prior year results.
Gross Margin Positive Trend Gross margin achieved 3.1% positive result for 2025, up from (0.4)% in 2024, showing profitability trend.
リスク要因
Continued Net Losses Expect continued net losses; achieving sustained positive cash flow remains uncertain without further revenue growth.
Platform Commercial Success Business heavily depends on commercial success of Growth Direct platform adoption rates and market acceptance.
Supply Chain Reliance Manufacturing relies on third-party suppliers, creating vulnerability to shortages and price fluctuations impacting supply continuity.
Limited Operating History Limited operating history makes future prospects and challenges difficult to evaluate accurately against competitors.
見通し
Cementing Market Standard Leverage first-mover advantage to define Growth Direct standard in rapidly growing bioprocessing manufacturing segment.
Global Customer Conversion Drive global adoption by converting top 50 pharmaceutical companies and leading CDMOs across target geographies.
Platform Value Increase Invest in launching new applications, hardware, and software to increase platform value incrementally for clients.
Distribution Expansion MilliporeSigma distribution agreement facilitates global sales expansion across new industrial quality control fields.
同業比較
売上高 (TTM)
$105.66M
$77.36M
$71.61M
粗利益率 (最新四半期)
87.3%
86.7%
81.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| SGHT | $199.28M | -5.1 | -55.7% | 35.4% |
| PROF | $189.73M | -4.1 | -85.7% | 3.3% |
| TLSI | $164.91M | -5.2 | 137.2% | 97.5% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
16.1%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月7日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし